May 08, 2009
Teikoku Pharma USA Acquires Travanti Pharma Inc.

San Jose, California, May 8, 2009- Teikoku Pharma USA Inc. the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc, a privately held corporation that…

March 09, 2009
Teikoku Pharma USA and Eisai Co., Ltd Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil

San Jose, California, March 9, 2009—Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a…

February 25, 2009
Teikoku Enters into an Agreement with Eisai for the Development of a Transdermal Patch Formulation of Donepezil Hydrochloride

Teikoku Seiyaku Co., Ltd. (Headquarters: Kagawa, President and CEO: Shosaku Murayama, “Teikoku Seiyaku”) and its U.S. subsidiary, Teikoku Pharma USA, Inc. (Headquarters: California, President and CEO: Masahisa Kitagawa, “Teikoku USA”) have entered into the following…

February 27, 2007
Teikoku Pharma Announces Contract with Dermatrends to Study Transdermal Application of Anti-Psychotic Drug

Teikoku Pharma USA, Inc., announced today that it has entered into an agreement with Dermatrends, a drug delivery company, to develop a prototype patch formulation for the transdermal delivery of a widely used anti-psychotic pharmaceutical…

January 10, 2007
Versatis®, Lidocaine Medicated Plaster Approved by MHRA

Teikoku Pharma annouces that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Versatis® in the UK, a novel 5 % lidocaine medicated plaster, for the treatment of neuropathic pain associated with previous herpes…

February 01, 2006
Teikoku Enters into an Agreement with Altea Therapeutics for the Development, Manufacture, and Commercialization in Japan of a New Transdermal Therapy for Parkinson’s Disease

In furthering it’s strength in transdermal drug delivery, Teikoku signs an agreement with Altea Therapeutics to develop and commercialize a new patch therapy for managing Parkinson’s Disease, utilizing Altea Therapeutics’ PassPort technology.

March 31, 2005
Study Compares Lidoderm Patch and Celebrex for Osteoarthritis Pain

Endo Pharmaceuticals has released clinical trial data that found patients receiving either Lidoderm or Celebrex 200 mg for pain associated with osteoarthritis (OA) of the knee experienced improvement in average daily pain intensity. Lidoderm (lidocaine…

December 02, 2004
Teikoku Pharma Expands Manufacturing Capabilities to the United States

Teikoku today announced its relocation to San Jose, California. The success of Lidoderm and the growth of US business prompted the move. Located in San Jose’s Innovation Triangle, this new facility, at 75,000 square feet…


Contact us for distribution or licensing opportunities, or to learn more about our growing portfolio of life-changing drug therapies.

"*" indicates required fields